中生方政NBF品牌怎么样 申请店铺

我要投票 中生方政NBF在医疗器械行业中的票数:837 更新时间:2025-09-03
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!将品牌入驻外推网,定制中生方政NBF品牌推广信息,可以显著提高中生方政NBF产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

蔚来李斌:四季度目标是平均每个月5万台交付量

9月2日,蔚来创始人、董事长、CEO李斌在2025年二季度财报电话会上表示,今年四季度的目标是能做到平均每个月5万台的交付量,也就是说三个品牌的整个季度交付量总计能超过15万台。(第一财经)

4小时前

湖南:支持培育一批人工智能优势企业

36氪获悉,据长沙发布,9月2日,湖南省委书记沈晓明在长沙调研人工智能产业发展并主持召开座谈会。沈晓明指出,要进一步明确发展方向,充分发挥湖南特色和优势,大力推动人工智能与先进制造、文化、现代农业、医学等领域融合发展。要进一步明确发展重点,支持培育一批人工智能优势企业,前瞻布局未来应用场景,提升湖南人工智能领域的核心竞争力。要进一步明确发展目标,围绕人工智能基础研究、产业发展、应用场景培育、人才培养等方面细化目标任务和工作举措,确保人工智能安全、稳健、可持续发展。

4小时前

咖啡连锁品牌Black Rock拟赴美IPO,目标估值8.61亿美元

咖啡连锁品牌Black Rock Coffee Bar于周二表示,其计划在纽约首次公开募股(IPO)中寻求最高8.607亿美元的估值。这家总部位于亚利桑那州斯科茨代尔的公司计划发行1470万股股票,每股发行价区间为16美元至18美元,按此计算,募资额最高可达2.65亿美元。(新浪财经)

4小时前

*ST春天:不存在其他应披露而未披露的重大信息

36氪获悉,*ST春天公告,公司股票在2025年8月29日、9月1日、9月2日连续3个交易日内日收盘价格涨幅偏离值累计达到12%,属于股票交易异常波动。经自查及向控股股东、实际控制人发函核实,截至公告披露日,除已披露事项外,不存在其他应披露而未披露的重大事项。公司近期日常经营情况和外部环境较前期未发生重大变化,生产经营情况正常。控股股东及实际控制人确认除已披露信息外,不存在其他应披露而未披露的重大信息。

4小时前

华盛昌:“DeepSense深度感测大模型”备案通过

36氪获悉,华盛昌公告,近日,“DeepSense深度感测大模型”正式通过生成式人工智能服务备案。该大模型主要应用于仪器仪表、专业测量和检测等相关行业,为下游应用企业和专业人员提供智能化、高效化的专业技术支持和一体化解决方案。备案通过意味着公司在“AI+测量智能体”领域取得阶段性成果,可以为行业客户提供行业领先的测量类垂域大模型,更为下游客户提供“AI+传感器”的工业领域深度感测解决方案,助力工业和专业领域实现设备效能提升、生产流程闭环控制与数字化管理转型。

4小时前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询